Regenesis Biomedical Completes $5.3M Series C Financing

Regenesis Biomedical, Inc., a Scottsdale, Arizona-based medical technology company that focuses on developing and marketing regenerative medicine products, completed a $5.3m Series C equity financing.

The round was led by Fulcrum Equity Partners
and TGap Ventures
, with participation from existing investor Solstice Capital.

In conjunction with the funding, Tom Greer of Fulcrum and Jack Ahrens of TGap will join Regenesis’ Board of Directors.

The company intends to use the new capital to accelerate the expansion of its sales team.

Led by President and CEO Virginia Rybski, Regenesis Biomedical developed, patented, and now markets the Provant Therapy System, which uses uses pulsed radio frequency energy (PRFE) to facilitate reduction of the pain and edema associated with post-operative, superficial soft tissues.

The company’s customers include acute care hospitals, long-term acute care hospitals, skilled nursing facilities and outpatient clinics.



Join the discussion